undamentalytics Newsletter
Sign in

Sight Sciences, Inc. revenue

Sight Sciences, Inc.'s revenue was $77.4m in fiscal 2025, down 3.1% on the year before. Since fiscal 2020 ($27.6m) it has grown at a compound 22.9% a year. Over the last twelve months it was $83.4m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue28497181807783
Growth on the year before—+77.1%+45.7%+13.6%−1.5%−3.1%—
Gross profit18405969686773
Gross margin66.7%82.4%82.7%85.3%85.5%86.2%88.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Surgical Glaucoma $75.7M 97.9% ▼ 0.2%
Dry Eye $1.6M 2.1% ▼ 58.7%

From Sight Sciences, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Sight Sciences, Inc. $83.4m 9.3% 0.8%
Tela Bio, Inc. $79.9m 6.1% 17.6%
PRO DEX Inc $79.6m 13.3% 19.2%
Pulmonx Corp $87.4m -3.4% 13.0%
Iradimed Corp $89.3m 11.0% 12.4%
Avita Medical, Inc. $75.6m 1.0% 22.8%

Compare with peers

Head to head: SGHT vs TELAPDEX vs SGHTLUNG vs SGHTIRMD vs SGHT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Sight Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sight Sciences, Inc.